Read Our First ESG Report
Tuesday, November 8th 2022
mRNA Access aims to accelerate the creation of new vaccines using mRNA technology in collaboration with global partners.
Through the program, researchers beyond Moderna can take advantage of the flexibility afforded by our platform to develop novel mRNA medicines for emerging and neglected infectious diseases.
At Moderna, we understand that the COVID-19 pandemic will not be our last. And our mission is to support scientists around the world as they work to protect our global health.